Peptic Ulcer Disease

Categories: Gastrointestinal diseases

Aliases & Classifications for Peptic Ulcer Disease

MalaCards integrated aliases for Peptic Ulcer Disease:

Name: Peptic Ulcer Disease 12 15
Peptic Ulcer 36 29 54 42 44 70
Acute Peptic Ulcer Without Hemorrhage and Without Perforation 12
Acute Peptic Ulcer with Hemorrhage and Perforation 12
Acute Peptic Ulcer with Hemorrhage 12


External Ids:

Disease Ontology 12 DOID:750
KEGG 36 H01634
ICD9CM 34 533
MeSH 44 D010437
NCIt 50 C3318
SNOMED-CT 67 155701001
ICD10 32 K27
UMLS 70 C0030920

Summaries for Peptic Ulcer Disease

MedlinePlus : 42 A peptic ulcer is a sore in the lining of your stomach or your duodenum, the first part of your small intestine. A burning stomach pain is the most common symptom. The pain Starts between meals or during the night Briefly stops if you eat or take antacids Lasts for minutes to hours Comes and goes for several days or weeks Peptic ulcers happen when the acids that help you digest food damage the walls of the stomach or duodenum. The most common cause is infection with a bacterium called Helicobacter pylori. Another cause is the long-term use of nonsteroidal anti-inflammatory medicines (NSAIDs) such as aspirin and ibuprofen. Stress and spicy foods do not cause ulcers, but can make them worse. To see if you have an H. pylori infection, your doctor will test your blood, breath, or stool. Your doctor also may look inside your stomach and duodenum by doing an endoscopy or x-ray. Peptic ulcers will get worse if not treated. Treatment may include medicines to reduce stomach acids or antibiotics to kill H. pylori. Antacids and milk can't heal peptic ulcers. Not smoking and avoiding alcohol can help. You may need surgery if your ulcers don't heal. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Peptic Ulcer Disease, also known as peptic ulcer, is related to gastrointestinal ulceration, recurrent, with dysfunctional platelets and active peptic ulcer disease, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Peptic Ulcer Disease is S100A8 (S100 Calcium Binding Protein A8), and among its related pathways/superpathways are PEDF Induced Signaling and Cytokine Signaling in Immune system. The drugs Potassium citrate and Aspirin have been mentioned in the context of this disorder. Affiliated tissues include small intestine, pancreas and cortex, and related phenotypes are Reduced mammosphere formation and cardiovascular system

KEGG : 36 Peptic ulcer is a common disorder of gastrointestinal system characterized by mucosal damage secondary to pepsin and gastric acid secretion. It usually occurs in the stomach and proximal duodenum. Typical symptoms include episodic burning epigastric pain, loss of appetite, and weight loss. Pain usually occurs two to five hours after meals or on an empty stomach. The most common causes of peptic ulcer are Helicobacter pylori infection and use of nonsteroidal anti-inflammatory drugs (NSAIDs). Smoking increases the risk of ulcer recurrence and slows healing. Most patients are treated successfully with eradication of H. pylori and/or avoidance of NSAIDs, along with the appropriate use of antisecretory therapy. About 25 percent of patients with peptic ulcer have a serious complication such as hemorrhage, perforation, or gastric outlet obstruction. Administration of proton pump inhibitors (PPIs) and endoscopic therapy control most bleeds.

Wikipedia : 73 Peptic ulcer disease (PUD) is a break in the inner lining of the stomach, the first part of the small... more...

Related Diseases for Peptic Ulcer Disease

Diseases related to Peptic Ulcer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 829)
# Related Disease Score Top Affiliating Genes
1 gastrointestinal ulceration, recurrent, with dysfunctional platelets 32.3 S100A8 PTGS2 PTGS1 HRH2 GAST
2 active peptic ulcer disease 32.3 PTGS2 PTGS1 HRH2 CYP2C19 ATP4A
3 multiple endocrine neoplasia, type i 32.0 SCT MEN1 GHRL GAST
4 zollinger-ellison syndrome 32.0 SCT MEN1 HRH2 GRP GAST ATP4A
5 peptic ulcer perforation 31.8 S100A8 HRH2 ATP4A
6 helicobacter pylori infection 31.7 TNF IL1RN IL1B IL10 CYP2C19 CXCL8
7 duodenitis 31.5 TNF S100A8 GAST ATP4A
8 opisthorchiasis 31.1 TNF IL1B CXCL8
9 gastric adenocarcinoma 31.0 TP53 S100A8 PTGS2 HRAS GAST
10 duodenal ulcer 31.0 TNF SCT S100A8 IL1RN IL1B IL10
11 gastroduodenitis 31.0 GAST ATP4A
12 dumping syndrome 31.0 SCT GHRL GAST
13 duodenogastric reflux 30.9 SCT GAST ATP4A
14 gastric ulcer 30.9 TP53 TNF S100A8 PTGS2 PTGS1 IL1RN
15 peritonitis 30.8 TNF IL1B IL10 CXCL8
16 microinvasive gastric cancer 30.8 TP53 S100A8 GAST ATP4A
17 gastric lymphoma 30.8 TP53 S100A8 ATP4A
18 irritable bowel syndrome 30.8 TNF IL1B IL10 GHRL CXCL8
19 lymphoma, mucosa-associated lymphoid type 30.8 TP53 S100A8 CXCL8 ATP4A
20 atherosclerosis susceptibility 30.8 TNF PPARG IL1B CXCL8
21 bile reflux 30.7 SCT S100A8 PTGS2 GAST ATP4A
22 bronchitis 30.7 TNF IL1B IL10 CXCL8
23 superior mesenteric artery syndrome 30.7 HRH2 ATP4A
24 aortic aneurysm, familial abdominal, 1 30.7 TNF IL1B IL10 CXCL8
25 end stage renal disease 30.7 TNF IL1RN IL1B IL10
26 aspiration pneumonitis 30.7 TNF HRH2 CXCL8 ATP4A
27 ileus 30.7 TNF IL1B IL10 GHRL
28 anthracosis 30.6 TNF IL1B CXCL8
29 allergic disease 30.6 TNF IL1B IL10 CXCL8
30 stomach disease 30.6 PTGS2 PTGS1 HRH2 GHRL
31 gastrinoma 30.6 SCT MEN1 GRP GAST
32 esophagitis 30.6 TP53 TNF PTGS2 IL1B IL10 HRH2
33 diarrhea 30.6 TNF SCT IL1B IL10 GAST CXCL8
34 obstructive jaundice 30.5 TNF GRP CXCL8
35 rosacea 30.5 TNF S100A8 CXCL8
36 hernia, hiatus 30.5 HRH2 GHRL GAST CYP2C19 ATP4A
37 intestinal obstruction 30.5 TNF GHRL ATP4A
38 islet cell tumor 30.5 SCT MEN1 GAST
39 liver cirrhosis 30.5 TP53 TNF SCT PPARG IL1B IL10
40 chronic kidney disease 30.5 TNF PPARG IL1B IL10 GHRL
41 gastric cancer 30.5 TP53 S100A8 PTGS2 IL1RN IL1B HRH2
42 gastroenteritis 30.4 TNF IL1RN IL1B IL10 HRH2 CXCL8
43 peptic esophagitis 30.4 TNF S100A8 PTGS2 IL1B HRH2 GAST
44 enterocolitis 30.4 TNF IL10 CXCL8
45 hepatitis a 30.4 TNF IL1B IL10
46 stomatitis 30.4 TNF IL1B IL10 CXCL8
47 spondylitis 30.4 TNF IL1B IL10
48 pulmonary disease, chronic obstructive 30.3 TNF IL1B IL10 CXCL8
49 appendicitis 30.3 TNF IL1B IL10 CXCL8
50 pyoderma 30.3 TNF IL1B CXCL8

Comorbidity relations with Peptic Ulcer Disease via Phenotypic Disease Network (PDN):

Acute Cystitis

Graphical network of the top 20 diseases related to Peptic Ulcer Disease:

Diseases related to Peptic Ulcer Disease

Symptoms & Phenotypes for Peptic Ulcer Disease

UMLS symptoms related to Peptic Ulcer Disease:

nausea and vomiting; constipation; abdominal pain; diarrhea; dyspepsia; icterus; signs and symptoms, digestive; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ATP4A CXCL8 GHRL HRAS MEN1 PPARG

MGI Mouse Phenotypes related to Peptic Ulcer Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.14 GRP HRAS IL10 IL1B IL1RN MEN1
2 homeostasis/metabolism MP:0005376 10.13 ATP4A GAST GHRL GRP HRAS HRH2
3 digestive/alimentary MP:0005381 10.11 ATP4A GAST GHRL HRAS HRH2 IL10
4 endocrine/exocrine gland MP:0005379 10.1 ATP4A GAST GHRL HRAS HRH2 IL10
5 integument MP:0010771 9.81 HRAS IL10 IL1B IL1RN PPARG PTGS1
6 muscle MP:0005369 9.56 HRAS IL10 MEN1 PPARG PTGS1 PTGS2
7 neoplasm MP:0002006 9.36 ATP4A GAST HRAS IL10 IL1B MEN1

Drugs & Therapeutics for Peptic Ulcer Disease

Drugs for Peptic Ulcer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
Clarithromycin Approved Phase 4 81103-11-9 84029
Coal tar Approved Phase 4 8007-45-2
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
Azithromycin Approved Phase 4 83905-01-5 447043 55185
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
Metronidazole Approved Phase 4 443-48-1 4173
Ofloxacin Approved Phase 4 82419-36-1 4583
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
Misoprostol Approved Phase 4 59122-46-2 5282381
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
Furazolidone Experimental, Vet_approved Phase 4 67-45-8 5323714 3435
20 Analgesics, Non-Narcotic Phase 4
21 Fibrinolytic Agents Phase 4
22 Analgesics Phase 4
23 Antirheumatic Agents Phase 4
24 Cyclooxygenase Inhibitors Phase 4
25 Anti-Inflammatory Agents Phase 4
26 Antipyretics Phase 4
27 Anti-Inflammatory Agents, Non-Steroidal Phase 4
28 Purinergic P2Y Receptor Antagonists Phase 4
29 Respiratory System Agents Phase 4
30 Cytochrome P-450 CYP3A Inhibitors Phase 4
31 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
32 Erythromycin Estolate Phase 4
33 Erythromycin stearate Phase 4
34 Erythromycin Ethylsuccinate Phase 4
35 Cyclooxygenase 2 Inhibitors Phase 4
36 Expectorants Phase 4
37 diuretics Phase 4
38 Antitubercular Agents Phase 4
39 Antibiotics, Antitubercular Phase 4
40 Cytochrome P-450 Enzyme Inhibitors Phase 4
41 Anti-Bacterial Agents Phase 4
42 Anti-Infective Agents Phase 4
43 Anticoagulants Phase 4
44 Antiparasitic Agents Phase 4
45 Antiprotozoal Agents Phase 4
46 Monoamine Oxidase Inhibitors Phase 4
47 Anti-Infective Agents, Local Phase 4
Acetylcysteine Approved, Investigational Phase 2, Phase 3 616-91-1 12035
Metformin Approved Phase 2, Phase 3 657-24-9 4091 14219
Iron Approved Phase 2, Phase 3 7439-89-6 23925 29936

Interventional clinical trials:

(show top 50) (show all 174)
# Name Status NCT ID Phase Drugs
1 Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding Unknown status NCT00687336 Phase 4
2 A Double Blind Study Comparing Low Dose and High Dose IV Esomeprazole After Successful Endoscopic Therapy in Patients With Peptic Ulcer Bleeding Unknown status NCT01275937 Phase 4 Esomeprazole;esomeprazole
3 Compare Gastric Acid Suppression of Esomeprazole by Oral or Intravenous Administration - A Randomized Trial Unknown status NCT00471029 Phase 4 esomeprazole
4 Protective Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Unknown status NCT02175186 Phase 4 ALBIS;Placebo
5 A Clinical Study of the Efficacy of Esomeprazole or Rabeprazole on the Pattern of Release of Pro- and Anti-inflammatory Cytokines From Gastric Mucosa of Patients With Peptic Ulcer Disease Completed NCT00534443 Phase 4
6 Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection Completed NCT00656968 Phase 4 10-day sequential treatment;10-day concomitant therapy
7 The Therapeutic Role of Albumin Supply on Peptic Ulcer Bleeding and the Correlation Between Clinical Course and Expression of Serum Response Factor on Ulcer Tissue and Superoxide Free Radical in Blood Completed NCT01822600 Phase 4 Human albumin;Omeprazole
8 A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers Completed NCT01353144 Phase 4 aspirin
9 Comparison of Conventional Triple Therapy Versus Sequential Therapy for H. Pylori in Peptic Ulcer Disease: Prospective Randomized Trial Completed NCT01418300 Phase 4 sequential versus triple
10 The Feasibility of Fast-track Surgery for Perforated Peptic Ulcers. A Prospective Randomized Clinical Trial Completed NCT01620671 Phase 4
11 Effects of 2 Different Doses of Pantoprazole on Gastric pH and Recurrent Bleeding in Patients Who Bled From Peptic Ulcers Completed NCT00279123 Phase 4 pantoprazole infusion;pantoprazole bolus;no treatment
12 The Studies of the Pathophysiologic Mechanisms of Poor Ulcer Healing & Clinical Improvement to the High Ulcer Rebleeding Rate for Patients With Comorbid Illnesses Completed NCT01591083 Phase 4 esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)
13 Comparison of Hemostatic Efficacy for Argon Plasma Coagulation vs Hemoclipping Following Distilled Water Injection in Treating High-risk Bleeding Ulcers Completed NCT04366583 Phase 4
14 The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy Completed NCT00840008 Phase 4
15 Phase 4 Study of Intravenous Proton Pump Inhibitor in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial Completed NCT00731601 Phase 4 pantoprazole;pantoprazole
16 Secondary Prevention With Long-term Oral Esomeprazole for Peptic Ulcer Recurrence and Rebleeding in High-risk Rockall Scores ≥ 6 Patients Completed NCT02456012 Phase 4 oral esomeprazole 20 mg twice daily;oral esomeprazole 20 mg once daily
17 Famotidine vs. Pantoprazole to Prevent Recurrent Aspirin-Induced Peptic Ulcer/Erosion - a Randomized Controlled Study Completed NCT00843063 Phase 4 pantoprazole vs famotidine
18 Administration of Intravenous Proton Pump Inhibitor Prior to Endoscopy [APPE] in Patients With Upper Gastrointestinal Bleeding; a Double-Blind Placebo-Controlled Randomised Study. Completed NCT00164866 Phase 4 Omeprazole
19 Eradication of Helicobacter Pylori According to 23S rRNA Point Mutations Associated With Clarithromycin Resistance Completed NCT01453036 Phase 4
20 Prevention of Recurrent Idiopathic Gastroduodenal Ulcer Bleeding: a Double-blind Randomized Trial Completed NCT01180179 Phase 4 Lansoprazole;Famotidine
21 Comparison of High Dose Infusion and Low Dose Bolus Intravenous Omeprazole for Treatment of Bleeding Ulcer With Adherent Clot Completed NCT02536989 Phase 4 omeprazole;omeprazole
22 The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in Helicobacter Pylori Patients Completed NCT02648659 Phase 4 Ilaprazole;Amoxicillin;Clarithromycin;Metronidazole
23 Comparison of Azithromycin or Clarithromycin in 3drugs Protocol of H-pylori Eradication Regimen Completed NCT01667692 Phase 4 azithromycin;clarithmycin
24 A Multicenter, Randomized, Active-Controlled Comparison Study of the Incidence of Gastroduodenal Ulcers Associated With Celecoxib and Low Dose ASA Versus Naproxen and Low Dose ASA in Healthy Subjects (50-75 Years of Age) Completed NCT00137033 Phase 4 Celecoxib;Naproxen;ASA
25 Helicobacter Pylori Eradication With Berberine Hydrochloride,Esomeprazole,Amoxicillin and Clarithromycin Versus Bismuth,Esomeprazole,Amoxicillin,and Clarithromycin: a Randomized,Open-label, Non-inferiority, Phase Ⅳ Trail Completed NCT02296021 Phase 4 Berberine;Bismuth;esomeprazole;amoxicillin;clarithromycin
26 Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan Completed NCT02241044 Phase 4
27 A Randomized, Double-blind Clinical Trial Comparing Zegerid Capsule to Famotidine in Preventing Anastomotic (Marginal) Ulcers in Post Gastric Bypass Patients Completed NCT00557349 Phase 4 Omeprazole;Famotidine
28 Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori Completed NCT01667575 Phase 4 Esomeprazole;Amoxicillin;Clarithromycin;Bismuth Potassium Citrate
29 Helicobacter Pylori Eradication With Berberine Hydrochloride, Lansoprazole, Amoxicillin and Bismuth Versus Clarithromycin Bismuth, Lansoprazole and Amoxicillin: A Randomized, Open-label, Non-inferiority, Phase Ⅳ Trial Completed NCT02633930 Phase 4 Berberine;clarithromycin;Bismuth;Lansoprazole;amoxicillin
30 A Randomized, Blinded, Placebo-Controlled Study of the Effect of Naproxen, Aspirin, Celecoxib, or Clopidogrel on Gastroduodenal Healing Completed NCT00778193 Phase 4 Naproxen;Aspirin;Celecoxib;Clopidogrel;Placebo
31 Helicobacter Pylori Treatment Completed NCT01668927 Phase 4 Proton Pump Inhibitor;Bismuth;Metronidazole;Tetracycline;Furazolidone;Amoxicillin
32 Levofloxacin-containing Therapy for Helicobacter Pylori Treatment Completed NCT01667718 Phase 4 Bismuth;Lansoprazole;Levofloxacin;Amoxicillin
33 Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line Helicobacter Pylori Eradication Completed NCT02175901 Phase 4 Lansoprazole;Bismuth Potassium Citrate;Amoxicillin;Metronidazole;Clarithromycin
34 Intravenous Administration of Metronidazole, Levofloxacin and Esomeprazole Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease Recruiting NCT04432233 Phase 4 Esomeprazole;Metronidazole;Levofloxacin
35 Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer: a Double-blind Randomised Trial on Misoprostol Combined With Lansoprazole Versus Lansoprazole Alone (NRT_MISO Study) Recruiting NCT03675672 Phase 4 Misoprostol Oral Tablet;Placebo Oral Tablet
36 A Multi-centre, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Phase 4 Efficacy and Safety Study of P-CAB (Tegoprazan 50 mg Once Daily) Compared With PPI (Rabeprazole 20 mg Once Daily) to Reduce Upper Gastrointestinal Events Including Bleeding and Symptomatic Ulcer Disease Not yet recruiting NCT04416581 Phase 4 PPI;P-CAB 25;P-CAB 50
37 Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy Not yet recruiting NCT04678492 Phase 4 Esomeprazole;Amoxicillin;Bismuth;Esomeprazole;Tetracycline;Furazolidone
38 Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers Terminated NCT00838682 Phase 4 omeprazole sodium IV;Rabeprazole
39 Low Dose Against High Dose of Proton Pump Inhibitors in Treatment Acute Peptic Ulcer Bleeding Withdrawn NCT02724150 Phase 4 Omeprazole High dose;Omeprazole Low dose
40 Oral vs Intravenous Proton Pump Inhibitor(PPI) in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial Withdrawn NCT01123031 Phase 4 lansoprazole;esomeprazole
41 A Prospective, Randomized Trial Comparing the Effect of Intravenous Omeprazole to That of Intravenous Ranitidine on the Maintenance of Hemostasis After Successful Endoscopic Treatment of Bleeding Peptic Ulcer Withdrawn NCT00247130 Phase 4 Omeprazole;Ranitidine
42 Clinical Effectiveness of Intravenous Esomeprazole Versus Pantoprazole in Preventing Peptic Ulcer Recurrent Bleeding: a Double-Blind Randomized Trial Withdrawn NCT00881413 Phase 4 Esomeprazole;Pantoprazole
43 Evaluation of the Efficacy and Safety of Different Duration of Proton Pump Inhibitor for Prevention of Upper Gastrointestinal Mucosal Injury in Patients Taking 12-month Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery Withdrawn NCT03038009 Phase 4 Pantoprazole
44 Oral Versus Intravenous Proton Pump Inhibitor Treatment in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis: a Prospective Randomized Comparative Study Unknown status NCT01182597 Phase 3 Pantoprazole (Pantoloc);Lansoprazole (Takepron OD)
45 Comparison of the Percentage Chronic on-Demand Users Treated With 20 Mg Pantoprazole on-Demand and Placebo o.d Versus Placebo on-Demand and 20 Mg Pantoprazole o.d. After Symptom Relief With 20 Mg Pantoprazole o.d. Unknown status NCT00161096 Phase 3 pantoprazole 20 mg (drug)
46 Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy Unknown status NCT02882477 Phase 2, Phase 3 Deferiprone;Acetylcysteine;Sitagliptin and Metformin
47 Intravenous Infusion of High Dose Omeprazole Versus Regular Dose Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers Completed NCT00519519 Phase 3 Omeprazole
48 An Efficacy and Safety Study of Intravenous Pantoprazole in the Prevention of Recurrent Peptic Ulcer Bleeding After Successful Hemostasis Completed NCT00040495 Phase 3 Pantoprazole
49 Phase 3 Study of Prospective Randomized Trial Comparing Adjunctive High Dose Omeprazole Infusion Against Scheduled Second Endoscopy in the Prevention of Peptic Ulcer Rebleeding After Therapeutic Endoscopy Completed NCT00164931 Phase 3 Intravenous omeprazole infusion
50 Efficacy and Safety of Intravenous IIaprazole for Peptic Ulcer Bleeding: A Randomized, Double-Blind, Omeprazole-Controlled, Multicenter, and Phase 3 Trail in China Completed NCT03362281 Phase 3 Ilaprazole;Omeprazole;Ilaprazole tablet;amoxicillin and clarithromycin

Search NIH Clinical Center for Peptic Ulcer Disease

Inferred drug relations via UMLS 70 / NDF-RT 51 :

Clidinium bromide
Hyoscyamine hydrobromide
Hyoscyamine Sulfate
methscopolamine bromide
methscopolamine nitrate
Propantheline Bromide

Cochrane evidence based reviews: peptic ulcer

Genetic Tests for Peptic Ulcer Disease

Genetic tests related to Peptic Ulcer Disease:

# Genetic test Affiliating Genes
1 Peptic Ulcer 29

Anatomical Context for Peptic Ulcer Disease

MalaCards organs/tissues related to Peptic Ulcer Disease:

Small Intestine, Pancreas, Cortex, Adrenal Cortex, Liver, Colon, Kidney

Publications for Peptic Ulcer Disease

Articles related to Peptic Ulcer Disease:

(show top 50) (show all 22158)
# Title Authors PMID Year
GWAS of peptic ulcer disease implicates Helicobacter pylori infection, other gastrointestinal disorders and depression. 42 61
33608531 2021
Banxia Xiexin Decoction in the treatment of Hp-associated peptic ulcer: A protocol for systematic review and meta-analysis. 61 42
33466180 2021
High- versus low-dose proton pump inhibitors post endoscopic hemostasis in hemodialysis cases with peptic ulcer bleeding. 42 61
33639687 2021
In situ expression of cagA and risk of gastroduodenal disease in Helicobacter pylori-infected children. 54 61
20038850 2010
DNA sequence analysis of cagA 3' motifs of Helicobacter pylori strains from patients with peptic ulcer diseases. 54 61
19850704 2010
[Results of evaluating the functional state of the gastric mucosa in duodenal peptic ulcer by means of a test gastropanel in workers engaged in the manufacture of nitrogen compounds]. 61 54
20387669 2010
Diverse characteristics of the CagA gene of Helicobacter pylori strains collected from patients from southern vietnam with gastric cancer and peptic ulcer. 61 54
19846630 2009
[Guidelines of prevention and treatment for NSAID-related peptic ulcers]. 54 61
19934612 2009
Distribution of Helicobacter pylori virulence markers in patients with gastroduodenal diseases in Pakistan. 54 61
19930551 2009
Disease association with two Helicobacter pylori duplicate outer membrane protein genes, homB and homA. 54 61
19545429 2009
Detection and evaluation of antibodies against neutrophil-activating protein of Helicobacter pylori in patients with gastric cancer. 54 61
19452583 2009
[Therapeutic and preventive effects of sulfate-chloride-sodium mineral water in experimental peptic ulcer]. 61 54
19639693 2009
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 61 54
18612816 2009
[Genetic features of Helicobacter pylori at patients with duodenal ulcer]. 54 61
20469711 2009
Helicobacter pylori and non-malignant diseases. 61 54
18783518 2008
Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib. 61 54
18711705 2008
Zollinger-Ellison syndrome: a personal perspective. 61 54
18646472 2008
vacA genotypes of Helicobacter pylori in relation to cagA status and clinical outcomes in Iranian populations. 54 61
18653971 2008
Differences in virulence markers between Helicobacter pylori strains from Iraq and those from Iran: potential importance of regional differences in H. pylori-associated disease. 54 61
18353934 2008
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. 54 61
18381949 2008
Epidemiology of acute upper gastrointestinal bleeding. 61 54
18346679 2008
Future expectations in the prophylaxis of intestinal bleeding. 61 54
18346690 2008
Prevalence of cagA in relation to clinical presentation of Helicobacter pylori infection in Egypt. 61 54
19086246 2008
Peptic ulceration may be a hormonal deficiency disease. 61 54
18280672 2008
Preferential induction of transforming growth factor-beta production in gastric epithelial cells and monocytes by Helicobacter pylori soluble proteins. 54 61
17922404 2007
Association between Helicobacter pylori genotypes and gastric disorders in relation to the cag pathogenicity island. 54 61
17521839 2007
Helicobacter pylori cagA and iceA genotypes status and risk of peptic ulcer in Saudi patients. 54 61
17334464 2007
Gastrinoma--morphological aspects. 61 54
17985091 2007
Helicobacter pylori cag pathogenicity island genes: clinical relevance for peptic ulcer disease development in Brazil. 61 54
17172510 2007
Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. 54 61
17088110 2006
Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. 54 61
17006979 2006
Association of H pylori cagA and vacA genotypes and IL-8 gene polymorphisms with clinical outcome of infection in Iranian patients with gastrointestinal diseases. 61 54
16937534 2006
Significance of cagA status and vacA subtypes of Helicobacter pylori in determining gastric histopathology: virulence markers of H. pylori and histopathology. 54 61
16724992 2006
[Microbiologic, serologic diagnosis, and genotypification of Helicobacter pylori isolated from biopsies in children and adult people. Molecular detection of the cag pathogenicity island of Helicobacter pylori]. 61 54
17578080 2006
Lower prevalence of Helicobacter pylori infection with vacAs1a, cagA-positive, and babA2-positive genotype in erosive reflux esophagitis disease. 54 61
16302983 2005
Clinical and pathological importance of vacA allele heterogeneity and cagA status in peptic ulcer disease in patients from North Brazil. 54 61
16444419 2005
No correlation of babA2 with vacA and cagA genotypes of Helicobacter pylori and grading of gastritis from peptic ulcer disease patients in Brazil. 54 61
16302986 2005
Poor metabolizer genotype status of CYP2C19 is a risk factor for developing gastric cancer in Japanese patients with Helicobacter pylori infection. 54 61
16268979 2005
[BabA2, oipA and cagE Helicobacter pylori genotypes in Colombian patients with gastroduodenal diseases]. 54 61
16276680 2005
Distinct diversity of vacA, cagA, and cagE genes of Helicobacter pylori associated with peptic ulcer in Japan. 54 61
16081930 2005
Clinical Relevance of the vacA, iceA, cagA, and flaA genes of Helicobacter pylori strains isolated in Eastern Taiwan. 61 54
15956417 2005
cagA gene variants in Malaysian Helicobacter pylori strains isolated from patients of different ethnic groups. 61 54
15866222 2005
Distribution of Helicobacter pylori cagA, cagE and vacA in different ethnic groups in Kuala Lumpur, Malaysia. 61 54
15836708 2005
cagA vacA alelles and babA2 genotypes of Helicobacter pylori associated with gastric disease in Brazilian adult patients. 54 61
15808313 2005
Zollinger-Ellison phenotype in the absence of hypergastrinemia and islet-cell tumor. 54 61
15879632 2005
Gastrointestinal effects of selective and non-selective non-steroidal anti-inflammatory drugs. 61 54
15892675 2005
Distribution of vacA alleles and cagA status of Helicobacter pylori in peptic ulcer disease and non-ulcer dyspepsia. 61 54
15606640 2004
Genetic polymorphism of interleukin-8 (IL-8) is associated with Helicobacter pylori-induced duodenal ulcer. 61 54
15627645 2004
Helicobacter pylori density and cagA status in cirrhotic patients: a case-control study. 61 54
15377296 2004
Diversity of vacA and cagA genes of Helicobacter pylori in Japanese children. 54 61
15298599 2004

Variations for Peptic Ulcer Disease

Expression for Peptic Ulcer Disease

Search GEO for disease gene expression data for Peptic Ulcer Disease.

Pathways for Peptic Ulcer Disease

Pathways related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show all 48)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
13.33 TP53 TNF PTGS2 IL1RN IL1B IL10
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.57 TP53 TNF IL1B IL10 HRAS
8 12.39 TP53 TNF IL1B CXCL8
Show member pathways
Show member pathways
11 12.27 TP53 PPARG MEN1 CXCL8
Show member pathways
12.25 TNF PTGS2 IL1B IL10
Show member pathways
12.25 TP53 TNF IL1B IL10 CXCL8
14 12.23 TNF IL1B DEFB4A CXCL8
Show member pathways
Show member pathways
Show member pathways
Show member pathways
19 12.1 TNF IL1RN IL1B IL10 CXCL8
20 12.07 TNF IL1B IL10 CXCL8
21 11.97 PTGS2 PTGS1 HRAS CYP2C19
22 11.92 TP53 IL1B HRAS CXCL8
23 11.91 TNF PTGS2 IL1B CXCL8
24 11.89 TNF IL1B IL10 CXCL8
25 11.88 TNF IL1B HRAS CXCL8
26 11.88 TP53 TNF PTGS2 IL1B CXCL8
27 11.78 TNF IL1B IL10
Show member pathways
11.75 TNF IL1B IL10
29 11.74 TNF IL1B IL10
30 11.73 TP53 HRAS CXCL8
31 11.73 TNF IL1B IL10 CXCL8
Show member pathways
33 11.66 TNF IL1B CXCL8
34 11.62 PTGS2 PTGS1 PPARG
Show member pathways
36 11.6 TNF IL1B CXCL8
37 11.55 TP53 PTGS2 CXCL8
38 11.52 TNF PTGS2 HRAS
39 11.49 TP53 TNF PTGS2 IL1B IL10 CXCL8
40 11.47 TP53 TNF HRAS
41 11.46 TNF IL1B IL10 CXCL8
42 11.37 TNF IL1B IL10
43 11.34 TNF IL1B IL10
44 11.24 TNF IL1B IL10
45 10.79 TNF PTGS2 IL1RN IL1B IL10 CXCL8
46 10.74 TNF PTGS2 PTGS1 CXCL8
47 10.39 SCT GRP GAST
48 10.13 HRH2 GAST ATP4A

GO Terms for Peptic Ulcer Disease

Cellular components related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 TNF SCT S100A8 IL1RN IL1B IL10
2 extracellular space GO:0005615 9.4 TNF SCT S100A8 IL1RN IL1B IL10

Biological processes related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.26 PPARG IL1RN IL1B IL10 HRH2 HRAS
2 G protein-coupled receptor signaling pathway GO:0007186 10.14 SCT PPARG HRH2 GRP GHRL GAST
3 positive regulation of gene expression GO:0010628 10.08 TP53 TNF IL1B HRAS CXCL8
4 fatty acid metabolic process GO:0006631 9.93 PTGS2 PTGS1 PPARG CYP2C19
5 response to lipopolysaccharide GO:0032496 9.91 S100A8 PTGS2 IL1B IL10
6 immune response GO:0006955 9.91 TNF IL1RN IL1B IL10 HRH2 DEFB4A
7 cellular response to lipopolysaccharide GO:0071222 9.9 TNF IL1B IL10 CXCL8
8 chemotaxis GO:0006935 9.89 S100A8 HRAS DEFB4A CXCL8
9 regulation of cell proliferation GO:0042127 9.89 TP53 TNF PTGS2 PTGS1 GHRL
10 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 TNF PPARG IL1B IL10
11 negative regulation of interleukin-6 production GO:0032715 9.84 TNF IL10 GHRL
12 regulation of blood pressure GO:0008217 9.83 PTGS2 PTGS1 PPARG
13 positive regulation of interferon-gamma production GO:0032729 9.82 TNF IL1B HRAS
14 response to organic substance GO:0010033 9.81 TNF PTGS2 PPARG IL10
15 inflammatory response GO:0006954 9.8 TNF S100A8 PTGS2 PTGS1 IL1RN IL1B
16 negative regulation of osteoblast differentiation GO:0045668 9.79 TNF PPARG MEN1
17 positive regulation of nitric oxide biosynthetic process GO:0045429 9.76 TNF PTGS2 IL1B
18 negative regulation of mitotic cell cycle GO:0045930 9.74 TP53 TNF IL10
19 response to glucocorticoid GO:0051384 9.73 TNF PTGS2 IL1RN IL10
20 decidualization GO:0046697 9.7 PTGS2 MEN1 GHRL
21 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.68 TP53 TNF
22 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.68 IL1RN IL10
23 cyclooxygenase pathway GO:0019371 9.68 PTGS2 PTGS1
24 response to molecule of bacterial origin GO:0002237 9.67 IL10 CXCL8
25 regulation of establishment of endothelial barrier GO:1903140 9.67 TNF IL1B
26 response to salt stress GO:0009651 9.67 TP53 TNF
27 endothelial cell apoptotic process GO:0072577 9.65 TNF IL10
28 positive regulation of lipid catabolic process GO:0050996 9.65 SCT IL1B
29 gastric acid secretion GO:0001696 9.65 HRH2 GHRL
30 embryonic digestive tract development GO:0048566 9.65 TNF SCT CXCL8
31 positive regulation of prostaglandin biosynthetic process GO:0031394 9.64 PTGS2 IL1B
32 vascular endothelial growth factor production GO:0010573 9.63 TNF IL1B
33 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.63 TNF IL1B IL10
34 negative regulation of cytokine production involved in immune response GO:0002719 9.62 TNF IL10
35 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.62 TP53 TNF PPARG IL10
36 sequestering of triglyceride GO:0030730 9.58 TNF IL1B
37 negative regulation of telomerase activity GO:0051974 9.58 TP53 PPARG MEN1
38 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.56 TNF IL1B
39 cytokine-mediated signaling pathway GO:0019221 9.5 TP53 TNF PTGS2 IL1RN IL1B IL10
40 positive regulation of fever generation GO:0031622 9.33 TNF PTGS2 IL1B
41 negative regulation of cell proliferation GO:0008285 9.23 TP53 PTGS2 PPARG MEN1 IL1B IL10

Molecular functions related to Peptic Ulcer Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription regulatory region sequence-specific DNA binding GO:0000976 9.56 TP53 TNF PPARG MEN1
2 arachidonic acid binding GO:0050544 9.16 S100A8 PPARG
3 cytokine activity GO:0005125 9.02 TNF IL1RN IL1B IL10 CXCL8
4 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS2 PTGS1

Sources for Peptic Ulcer Disease

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....